Симуляция графика K-линий, фактические данные указаны на торговой странице
Ключевые данные
Открытие вчера
$0.78
Пред. закрытие
$0.91
Вчерашний диапазон
$0.78 - $0.97
Диапазон 52 нед.
$0.78 - $3.96
Объем торговли
152.675K
МС
$46.959M
P/E
--
EPS
$-0.58
Обзор компании
NYSE
Rafael Holdings, Inc. owns commercial real estate assets and interests in preclinical and clinical stage pharmaceutical companies. The company is headquartered in Newark, New Jersey.
СекторREAL ESTATE
ОтрасльREAL ESTATE SERVICES
Штаб-квартира520 BROAD STREET, NEWARK, NJ, UNITED STATES, 07102
RFL represents Rafael Holdings, a company focused on the development and commercialization of cancer therapies. It supports promising companies in healthcare and technology through strategic investments. Rafael Holdings holds ownership in technologies related to drug development and aims to create innovative therapies to address critical healthcare needs.
Rafael Holdings operates in the healthcare sector and is primarily classified within the biotechnology industry. This positions the company in a dynamic space involving cutting-edge research and development of advanced medical treatments targeting various critical illnesses.
Rafael Holdings derives revenue primarily from investments in biotechnology ventures and the development of pharmaceutical candidates. Its main focus is the advancement of novel cancer therapies, which, upon successful commercialization, could represent a key driver for future income streams.
Investing in Rafael Holdings carries risks tied to its focus on biotechnology, including research and development uncertainties, regulatory hurdles, and long timelines to achieve product approvals. Additionally, reliance on successful clinical trials and market acceptance contributes to potential volatility.
Rafael Holdings does not currently pay dividends. As a biotechnology investment-focused company, its financial priorities are centered on reinvesting capital into drug development and research activities rather than distributing earnings.
In the biotechnology space, Rafael Holdings competes with other companies focused on cancer treatment, including large-cap firms like Amgen and Biogen, as well as smaller specialized biotech companies targeting oncology. Each competitor differs in research focus, scale, and market presence.
Rafael Holdings offers exposure to innovative cancer therapies and biotechnology investments. Investors may be intrigued by potential growth linked to successful clinical trials and commercialization. However, it is important to weigh these opportunities against the inherent risks of investing in the biotech sector.
Investors should consider Rafael Holdings’ pipeline of drug candidates, progress in clinical trials, and cash reserves for funding operations. The valuation reflects future expectations and risks in biotechnology development, making thorough due diligence essential for informed investment decisions.
Предупреждение о рисках
1.Цены на акции могут сильно колебаться, инвестируйте осторожно. Прошлые результаты не гарантируют будущую доходность.
2.Торговля цифровыми активами сопряжена с рыночными, техническими и иными рисками. Пожалуйста, принимайте взвешенные решения и рационально распределяйте активы.
3.Информация на этой странице предназначена только для ознакомления и не является инвестиционной рекомендацией.